Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033075 | 0.91 | MEN1 (0.54) | MEN1KMT2AGAAPDE5ACASP6 | |
| SCHEMBL1033062 | 0.90 | MEN1 (0.51) | MEN1KMT2AGAAPDE5ACASP6 | |
| SCHEMBL7638721 | 0.86 | KMT2A (0.48) | MEN1KMT2AGAAPDE5ACASP6 | |
| SCHEMBL9525943 | 0.84 | MEN1 (0.65) | MEN1KMT2AGAACASP6HPGD | |
| SCHEMBL3036904 | 0.82 | MEN1 (0.64) | MEN1KMT2AGAACASP6HPGD | |
| SCHEMBL6036703 | 0.80 | MEN1 (0.44) | MEN1KMT2AGAAPDE5ACASP6 | |
| SCHEMBL2982634 | 0.80 | GAA (0.59) | MEN1KMT2AGAACASP6HPGD | |
| SCHEMBL29651988 | 0.80 | GAA (0.59) | MEN1KMT2AGAACASP6HPGD | |
| SCHEMBL13941167 | 0.78 | MEN1 (0.77) | MEN1KMT2AGAACASP6HPGD | |
| SCHEMBL3020598 | 0.78 | MEN1 (1.00) | MEN1KMT2AGAACASP6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| EP-2275403-A1 | Process for phenylacetic acid derivatives | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1216226-B1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ALDH7A1, CYP4F11, CYP2A6 | MEN1 2959/4885KMT2A 1314/4885GAA 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.